130 related articles for article (PubMed ID: 16152782)
1. [Neutropenia induced by taxoids and its control with granulocyte colony-stimulating factor].
Luis-Fernández J; Rangel-Mayoral JF; Estepa-Alonso MJ; Liso-Rubio FJ
Invest Clin; 2005 Sep; 46(3):265-72. PubMed ID: 16152782
[TBL] [Abstract][Full Text] [Related]
2. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial.
Seibel NL; Blaney SM; O'Brien M; Krailo M; Hutchinson R; Mosher RB; Balis FM; Reaman GH
Clin Cancer Res; 1999 Apr; 5(4):733-7. PubMed ID: 10213206
[TBL] [Abstract][Full Text] [Related]
6. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Valero V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
[TBL] [Abstract][Full Text] [Related]
7. [Safety and efficacy study of the recombinant granulocyte colony-stimulating factor for prevention of neutropenia and neutropenia-related complications in women with metastatic breast cancer receiving docetaxel/doxorubicin].
Liutkauskiene S; Sveikata A; Juozaityte E; Characiejus D; Juodzbaliene E; Kregzdyte R; Fokas V
Medicina (Kaunas); 2009; 45(8):600-6. PubMed ID: 19773618
[TBL] [Abstract][Full Text] [Related]
8. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
Livingston RB; Ellis GK; Gralow JR; Williams MA; White R; McGuirt C; Adamkiewicz BB; Long CA
J Clin Oncol; 1997 Apr; 15(4):1395-400. PubMed ID: 9193331
[TBL] [Abstract][Full Text] [Related]
9. Peg-filgrastim and cabazitaxel in prostate cancer patients.
Di Lorenzo G; DʼAniello C; Buonerba C; Federico P; Rescigno P; Puglia L; Ferro M; Bosso D; Cavaliere C; Palmieri G; Sonpavde G; De Placido S
Anticancer Drugs; 2013 Jan; 24(1):84-9. PubMed ID: 23044721
[TBL] [Abstract][Full Text] [Related]
10. [Effect of G-CSF (nartograstim) on neutropenia (leukopenia) induced by taxane in metastatic breast cancer--time-course changes in neutrophil and leukocyte counts].
Kinoshita J; Haga S; Shimizu T; Imamura H; Watanabe O; Nagumo H; Utada Y; Okabe T; Kimura K; Hirano A; Kajiwara T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):815-9. PubMed ID: 11432350
[TBL] [Abstract][Full Text] [Related]
11. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
[TBL] [Abstract][Full Text] [Related]
12. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial.
Alexopoulos K; Kouroussis C; Androulakis N; Papadakis E; Vaslamatzis M; Kakolyris S; Samelis G; Patila E; Vossos A; Samantas E; Georgoulias V
Cancer Chemother Pharmacol; 1999; 43(3):257-62. PubMed ID: 9923557
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
Belani CP
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.
Sparano JA; Malik U; Rajdev L; Sarta C; Hopkins U; Wolff AC
J Clin Oncol; 2001 Jun; 19(12):3117-25. PubMed ID: 11408509
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer.
Shin E; Ishitobi M; Hiraoia M; Kazumasa F; Hideyuki M; Nishisho I; Toshiro S; Yasunori H; Tosimasa T
Anticancer Res; 2000; 20(6C):4721-6. PubMed ID: 11205207
[TBL] [Abstract][Full Text] [Related]
17. Pegfilgrastim: the promise of pegylation fulfilled.
Crawford J
Ann Oncol; 2003 Jan; 14(1):6-7. PubMed ID: 12488286
[No Abstract] [Full Text] [Related]
18. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer.
Belani CP; Aisner J; Hiponia D; Engstrom C
Semin Oncol; 1995 Aug; 22(4 Suppl 9):7-12. PubMed ID: 7544028
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
Blaney SM; Seibel NL; O'Brien M; Reaman GH; Berg SL; Adamson PC; Poplack DG; Krailo MD; Mosher R; Balis FM
J Clin Oncol; 1997 Apr; 15(4):1538-43. PubMed ID: 9193350
[TBL] [Abstract][Full Text] [Related]
20. An open-label multicenter safety, tolerability, and efficacy study of recombinant granulocyte colony-stimulating factor in the prevention of neutropenic complications in breast cancer patients.
Sveikata A; Liutkauskienė S; Juozaitytė E; Characiejus D; Tamošaitytė L; Šeštakauskas K
Medicina (Kaunas); 2011; 47(8):428-33. PubMed ID: 22123557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
